Business Context and Reporting Period
This Form 8-K was filed by Novus Therapeutics, Inc. (trading symbol: NVUS) on October 6, 2020, reporting events that occurred on October 5, 2020. The filing addresses a corporate action regarding the company's capital structure rather than operational financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure adjustment.
Material Changes
On October 5, 2020, the Company implemented a 1-for-18 reverse stock split of its issued and outstanding common stock. Key details include:
- Every 18 shares of common stock were automatically combined into one share.
- The stock continues to trade on the Nasdaq Capital Market under the symbol "NVUS" but with a new CUSIP number (67011N 204).
- The split proportionally adjusted the number of shares issuable upon conversion of preferred stock and the exercise/vesting of stock options, restricted stock units, and warrants.
- Conversion and exercise prices for these instruments were proportionately increased.
- No fractional shares were issued; holders entitled to fractional shares received cash payments in lieu thereof.
- The total number of authorized shares of common and preferred stock remained unchanged.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the mechanics of the stock split. The action was authorized by the Board of Directors at the 2020 Annual Meeting of Stockholders held on May 12, 2020, within an approved range of 1-for-10 to 1-for-30.
Investor Verification Checklist
- Verify the new CUSIP number (67011N 204) for trading and record-keeping purposes.
- Confirm the adjusted exercise prices and share counts for any held options, warrants, or convertible notes.
- Check for cash payments received in lieu of fractional shares if applicable.
- Review the Certificate of Amendment to the Restated Certificate of Incorporation (Exhibit 3.1) for legal specifics.